Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG)

被引：0
|
作者：
Al-Sawaf, O. [1 ]
Kluth, S. [1 ]
Bahlo, J. [1 ]
Hopfinger, G. [2 ]
Fink, A. M. [1 ]
Cramer, P. [1 ]
Maurer, C. [1 ]
Bergmann, M. [3 ]
Dreyling, M. [4 ]
Lange, E. [5 ]
Kneba, M. [6 ]
Stilgenbauer, S. [7 ]
Kiehl, M. G. [8 ]
Jaeger, U. [9 ]
Wendtner, C. M. [3 ]
Fischer, K. [1 ]
Hallek, M. [1 ,10 ]
Eichhorst, B. [1 ]
机构：
[1] Uniklin Koln, Ctr Integrierte Onkol Koln Bonn, Klin Innere Med 1, Deutsch CLL Studiengrp, Cologne, Germany
[2] Med Univ Wien, Univ Klin Innere Med 1, Vienna, Austria
[3] Klinikum Munchen Schwabing, Klin Hamatol Onkol Immunol Palliat Med Infektiol, Munich, Germany
[4] Klinikum Univ Munchen, Med Klin & Poliklin 3, Munich, Germany
[5] Evangel Krankenhaus Hamm, Klin Hamatol Onkol & Palliat Med, Hamm, Germany
[6] Univ Klinikum Schleswig Holstein, Klin Hamatol Onkol & Palliat Med, Kiel, Germany
[7] Uniklin Ulm, Klin Innere Med 3, Ulm, Germany
[8] Klinikum Frankfurt Oder, Med Klin 1, Frankfurt, Oder, Germany
[9] Allgemeines Krankenhaus Wien, Klin Abt Hamatol & Hamostaseol, Vienna, Austria
[10] Uniklin Koln, CECAD Cluster Excellence Cellular Stress Response, Cologne, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V685
引用
收藏
页码：212 / 213
页数：2
相关论文
共 50 条
  • [31] Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    Al-Sawaf, O.
    Robrecht, S.
    Bahlo, J.
    Fink, A. M.
    Cramer, P.
    Von Tresckow, J.
    Lange, E.
    Kiehl, M.
    Dreyling, M.
    Ritgen, M.
    Duerig, J.
    Tausch, E.
    Schneider, C.
    Stilgenbauer, S.
    Wendtner, C. M.
    Fischer, K.
    Goede, V
    Hallek, M.
    Eichhorst, B.
    LEUKEMIA, 2021, 35 (01) : 169 - 176
  • [32] Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials
    O. Al-Sawaf
    S. Robrecht
    J. Bahlo
    A. M. Fink
    P. Cramer
    J. v Tresckow
    E. Lange
    M. Kiehl
    M. Dreyling
    M. Ritgen
    J. Dürig
    E. Tausch
    C. Schneider
    S. Stilgenbauer
    C. M. Wendtner
    K. Fischer
    M. Goede
    B. Hallek
    Leukemia, 2021, 35 : 169 - 176
  • [33] CHOP plus rituximab (CHOP-R) in fludarabine (F) refractory chronic lymphocytic leukemia (CLL) or CLL with autoimmune hemolytic anemia (AIHA) or Richter's transformation (RT): First interim analysis of a phase II trial of the German CLL study group (GCLLSG).
    Eichhorst, BF
    Busch, R
    Duehrsen, U
    Schulz, H
    Wendtner, CM
    Goebeler, ME
    Hallek, M
    BLOOD, 2005, 106 (11) : 601A - 601A
  • [34] Subcutaneous Campath-1H (Alemtuzumab) in fludarabine-refractory CLL interim analysis of the CLL2h study of the German CLL study group (GCLLSG).
    Stilgenbauer, S
    Winkler, D
    Kröber, A
    Kienle, D
    Hallek, M
    Hensel, M
    Lengfelder, E
    Trümper, L
    Dreger, P
    Jäger, U
    Döhner, H
    BLOOD, 2004, 104 (11) : 140A - 140A
  • [35] Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia, (CLL):: results of a phase II study of the German CLL Study Group
    Hallek, M
    Schmitt, B
    Wilhelm, M
    Busch, R
    Kröber, A
    Fostitsch, HP
    Sezer, O
    Herold, M
    Knauf, W
    Wendtner, CM
    Kuse, R
    Freund, M
    Franke, A
    Schriever, F
    Nerl, C
    Döhner, H
    Thiel, E
    Hiddemann, W
    Brittinger, G
    Emmerich, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2001, 114 (02) : 342 - 348
  • [36] Chemoimmuno-Therapy with Fludarabine, Cyclophosphamide and Alemtuzumab in Patients with Relapsed/Refractory CLL: Interim Analysis of the CLL2L Trial of the German CLL Study Group
    Elter, Thomas
    James, Rojin
    Stilgenbauer, Stephan
    Ritgen, Matthias
    Hallek, Michael
    Engert, Andreas
    BLOOD, 2008, 112 (11) : 1087 - 1087
  • [37] Extended Follow up of the CLL8 Protocol, a Randomized Phase-III Trial of the German CLL Study Group (GCLLSG) Comparing Fludarabine and Cyclophosphamide (FC) to FC Plus Rituximab (FCR) for Previously Untreated Patients with Chronic Lymphocytic Leukemia (CLL): Results On Survival, Progression-Free Survival, Delayed Neutropenias and Secondary Malignancies Confirm Superiority of the FCR Regimen
    Fischer, Kirsten
    Bahlo, Jasmin
    Fink, Anna-Maria
    Busch, Raymonde
    Boettcher, Sebastian
    Mayer, Jiri
    Dreger, Peter
    Maurer, Christian
    Engelke, Anja
    Kneba, Michael
    Doehner, Hartmut
    Eichhorst, Barbara F.
    Wendtner, Clemens-Martin
    Stilgenbauer, Stephan
    Hallek, Michael
    BLOOD, 2012, 120 (21)
  • [38] Cyclophosphamide, Adriamycin, Vincristine and Prednisone Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Cytopenia (AIC) or Richter's Transformation (RT): Final Analysis of a Phase II Study of the German CLL Study Group
    Jenke, Petra
    Eichhorst, Barbara
    Busch, Raymonde
    Anheier, Nadine
    Duehrsen, Ulrich
    Duerig, Jan
    Dreyling, Martin H.
    Bergmann, Manuela
    Goebeler, Maria Elisabeth
    Hurts, Hans Juergen
    Stauch, Martina Beate
    Stilgenbauer, Stephan
    Doehner, Hartmut
    Fink, Anna-Maria
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Hallek, Michael
    BLOOD, 2011, 118 (21) : 1233 - 1234
  • [39] Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials
    Al-Sawaf, O.
    Robrecht, S.
    Bahlo, J.
    Fink, A. M.
    Cramer, P.
    Langerbeins, P.
    von Tresckow, J.
    Maurer, C.
    Kutsch, N.
    Lange, E.
    Kiehl, M.
    Fischer, K.
    Stilgenbauer, S.
    Wendtner, C-M
    Goede, V
    Hallek, M.
    Eichhorst, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 166 - 166
  • [40] Rituximab Maintenance In Patients with Chronic Lymphocytic Leukemia (CLL) After Upfront Treatment with Rituximab Plus Fludarabine, Cyclophosphamide, and Mitoxantrone (R-FCM): Final Results of a Multicenter Phase II Trial On Behalf of the Spanish CLL Study Group (GELLC)
    Bosch, Francesc
    Abrisqueta, Pau
    Villamor, Neus
    Jose Terol, Maria
    Gonzalez-Barca, Eva
    Gonzalez, Marcos
    Ferra, Christelle
    Abella, Eugenia
    Delgado, Julio
    Garcia-Marco, Jose A.
    Gonzalez, Yolanda
    Carbonell, Felix
    Ferrer, Secundino
    Monzo, Encarna
    Jarque, Isidro
    Muntanola, Ana
    Constants, Mireia
    Escoda, Lourdes
    Montserrat, Emili
    BLOOD, 2011, 118 (21) : 136 - 137
12345